EyePoint (EYPT) hits Phase 3 enrollment milestone, issues amended 8-K

Rhea-AI Filing Summary

Form 8-K/A overview: This amendment only fixes a broken hyperlink in the original 8-K filed 29 Jul 2025. The substance of the report is unchanged.

Material event (Item 8.01): EyePoint Pharmaceuticals (EYPT) has completed enrollment in its pivotal Phase 3 clinical trials of DURAVYU™ for wet age-related macular degeneration (wet AMD). Completion of enrollment marks the final operational step before data collection and analysis.

• Press release detailing the milestone is furnished as Exhibit 99.1.
• An updated investor presentation is furnished as Exhibit 99.2.

No financial results, guidance, or other transactions are disclosed. The filing signals continued pipeline progress but investors must await trial read-out for efficacy and safety outcomes.

Positive

• Enrollment in pivotal Phase 3 DURAVYU™ trials is complete, removing a key timeline risk and positioning the asset for imminent data read-out.
• Updated investor materials (Ex. 99.2) may enhance transparency with shareholders.

Negative

• No financial metrics or guidance were supplied, leaving revenue and cash-runway visibility unchanged.

Insights

Biotech Equity Analyst

TL;DR: Enrollment completion is a key inflection point; positive for timelines but lacks efficacy data, so impact is moderate.

Finishing Phase 3 enrollment for DURAVYU™ eliminates a major operational risk and starts the countdown to top-line data. This usually accelerates valuation discussions, especially for small-cap biotech names like EYPT, because the next catalyst becomes more visible. However, the 8-K/A contains no information on trial design changes, endpoints, or expected read-out dates, and therefore provides limited new insight into ultimate approval probability. Overall, the news is directionally positive but not transformational until data are available.

0001314102true00013141022025-07-292025-07-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2025

EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			000-51122	26-2774444
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
480 Pleasant Street
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 926-5000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001		EYPT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Form 8-K/A amends the Form 8-K filed on July 29, 2025, solely to correct a broken hyperlink. No other changes have been made.

Item 8.01 Other Events.

On July 29, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing it has completed enrollment in the pivotal Phase 3 clinical trials evaluating DURAVYU™ for the treatment of wet age-related macular degeneration ("wet AMD"). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

On the same date, the Company posted an updated investor presentation on its website at www.eyepointpharma.com. A copy of the presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1		Press Release of EyePoint Pharmaceuticals, Inc. dated July 29, 2025
99.2		Investor Presentation of EyePoint Pharmaceuticals, Inc. dated July 29, 2025
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			EYEPOINT PHARMACEUTICALS, INC.
Date:	July 29, 2025	By:	/s/ George O. Elston
			George O. Elston Executive Vice President and Chief Financial Officer

FAQ

What did EyePoint Pharmaceuticals (EYPT) announce in the 8-K/A?

The company reported completion of patient enrollment in its pivotal Phase 3 DURAVYU™ trials for wet AMD.

Why was the 8-K amended?

The /A corrects a broken hyperlink in the original 29 Jul 2025 filing; no substantive changes were made.

Are there any financial results included?

No. The filing contains no revenue, EPS, or cash metrics.

Where can investors find more details on DURAVYU™ progress?

EyePoint furnished a press release (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2).

Does enrollment completion guarantee FDA approval?

No. It only signals trial progress; approval depends on forthcoming Phase 3 efficacy and safety data.